↓ Skip to main content

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Overview of attention for article published in Alzheimer's Research & Therapy, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
6 tweeters
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
159 Dimensions

Readers on

mendeley
279 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Published in
Alzheimer's Research & Therapy, May 2016
DOI 10.1186/s13195-016-0189-7
Pubmed ID
Authors

Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth, Gerald Luscan, Bradley T. Wyman, Lisa Hua, Lingfeng Yang, H. Robert Brashear, Ronald S. Black

Abstract

Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease (AD). Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscale and the Disability Assessment for Dementia. A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event. These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed. Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810 ; registered 24 Apr 2008. Carriers (3001) ClinicalTrials.gov identifier NCT00676143 ; registered 2 May 2008.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 279 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
India 1 <1%
Belgium 1 <1%
Egypt 1 <1%
Unknown 274 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 43 15%
Student > Ph. D. Student 42 15%
Student > Master 39 14%
Researcher 36 13%
Other 17 6%
Other 34 12%
Unknown 68 24%
Readers by discipline Count As %
Medicine and Dentistry 48 17%
Neuroscience 48 17%
Biochemistry, Genetics and Molecular Biology 30 11%
Agricultural and Biological Sciences 18 6%
Pharmacology, Toxicology and Pharmaceutical Science 15 5%
Other 36 13%
Unknown 84 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2021.
All research outputs
#1,466,240
of 21,353,399 outputs
Outputs from Alzheimer's Research & Therapy
#235
of 1,098 outputs
Outputs of similar age
#26,736
of 280,711 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 21,353,399 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,098 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.1. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,711 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them